• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

    3/19/24 7:00:00 AM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SYBX alert in real time by email

    CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023.

    The Company recently announced the decision to discontinue Synpheny-3, its pivotal study of labafenogene marselecobac (SYNB1934) in phenylketonuria (PKU) and evaluate strategic options for the Company.

    Fourth Quarter 2023 Financial Results

    As of December 31, 2023, Synlogic had cash, cash equivalents, and short-term marketable securities of $47.7 million.

    Revenue was $2.8 million for the three months ended December 31, 2023, compared to $0.1 million for the corresponding period in 2022. Revenue in both periods was associated with the research collaboration with Roche. Research and development expenses were $10.2 million for the three months ended December 31, 2023, compared to $13.6 million for the corresponding period in 2022. General and administrative expenses for the three months ended December 31, 2023 were $3.2 million compared to $3.8 million for the corresponding period in 2022.

    For the three months ended December 31, 2023, Synlogic reported a consolidated net loss of $14.5 million, or $1.71 per share, compared to a consolidated net loss of $16.7 million, or $3.54 per share, for the corresponding period in 2022.

    Full Year 2023 Financial Results

    Revenues were $3.4 million for the year ended December 31, 2023, compared to $1.2 million for the same period in 2022. Revenue in both periods was associated with the research collaboration with Roche. Operating expenses were $58.5 million for the year ended December 31, 2023, compared to $68.6 million for the same period in 2022. For the year ended December 31, 2023, consolidated net loss was $57.3 million, or $8.81 per share, compared to a consolidated net loss of $66.1 million, or $13.83 per share, for the year ended December 31, 2022.

    About Synlogic 

    Synlogic is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases in need of new treatment options. Synlogic designs, develops and manufactures these drug candidates, which are produced by applying precision genetic engineering to well-characterized probiotics.

    Forward Looking Statements

    This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "look forward," "estimate," "expect," "focused on," "intend," "on track, " "plan," "predict" and similar expressions and their variants, as they relate to Synlogic, may identify forward-looking statements. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors, including: the Company may not execute its planned exploration and evaluation of strategic alternatives; the availability of suitable third parties with which to conduct contemplated strategic transactions; the risk that the Company's reduction in force efforts may not generate their intended benefits to the extent or as quickly as anticipated; and the risk that the Company's reduction in force efforts may negatively impact the Company's business operations and reputation as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.

    Synlogic, Inc.
    Condensed Consolidated Statements of Operations
    (unaudited)
    (in thousands,except share and per share data)       
      For the three months ended For the years ended
      December 31 December 31
       2023   2022   2023   2022 
    Revenue$2,769  $106  $3,371  $1,180 
             
    Operating expenses       
     Research and development 10,207   13,639   43,971   52,044 
     General and administrative 3,203   3,770   14,561   16,555 
    Total operating expenses 13,410   17,409   58,532   68,599 
    Loss from operations (10,641)  (17,303)  (55,161)  (67,419)
    Other income (expense), net (3,891)  607   (2,107)  1,272 
    Loss before income taxes (14,532)  (16,696)  (57,268)  (66,147)
    Income tax expense (1)  —   (14)  — 
    Net loss$(14,533) $(16,696) $(57,282) $(66,147)
             
    Net loss per share - basic and diluted$(1.71) $(3.54) $(8.81) $(13.83)
    Weighted-average common shares used in computing net loss per share - basic and diluted 8,523,567   4,716,175   6,502,279   4,781,696 
            



     Synlogic, Inc.
     Condensed Consolidated Balance Sheets
      
    (in thousands, except share data)   
      December 31, December 31,
       2023   2022 
    Assets   
     Cash, cash equivalents, & marketable securities$47,746  $77,629 
     Property and equipment, net 5,603   7,323 
     Other assets 22,201   25,913 
    Total assets$75,550  $110,865 
         
    Liabilities and stockholders' equity   
     Current liabilities$20,404  $12,122 
     Long-term liabilities 12,491   16,133 
     Total liabilities 32,895   28,255 
     Total stockholders' equity$42,655  $82,610 
    Total liabilities and stockholders' equity$75,550  $110,865 
         
    Common stock and common stock equivalents   
     Common stock 9,186,157   4,449,082 
     Common stock warrants (pre-funded) 2,973,183   169,874 
    Total common stock 12,159,340   4,618,956 

     

     

    ----

    Contact: [email protected]



    Primary Logo

    Get the next $SYBX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SYBX

    DatePrice TargetRatingAnalyst
    11/24/2021$7.00Perform → Outperform
    Oppenheimer
    11/24/2021Perform → Outperform
    Oppenheimer
    11/11/2021$15.00 → $11.00Outperform
    SVB Leerink
    10/13/2021$9.00 → $7.00Buy
    HC Wainwright & Co.
    9/20/2021$7.00 → $9.00Overweight
    Piper Sandler
    6/28/2021$13.00 → $9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SYBX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Synlogic Reports Third Quarter 2024 Financial Results

      WINCHESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the third quarter 2024 and provided a corporate update. As previously announced, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Synlogic Board of Di

      11/12/24 4:35:09 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Reports Second Quarter 2024 Financial Results

      WINCHESTER, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the second quarter 2024 and provided a corporate update. In March 2024, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Board has not set a timetab

      8/8/24 7:00:52 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Reports First Quarter 2024 Financial Results

      CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update. In March 2024, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Board has not set a timetable fo

      5/14/24 7:00:28 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Synlogic Inc.

      SC 13G/A - SYNLOGIC, INC. (0001527599) (Subject)

      11/14/24 4:40:57 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Synlogic Inc. (Amendment)

      SC 13D/A - SYNLOGIC, INC. (0001527599) (Subject)

      5/16/24 7:44:32 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Synlogic Inc.

      SC 13G - SYNLOGIC, INC. (0001527599) (Subject)

      4/18/24 11:18:42 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYBX
    Leadership Updates

    Live Leadership Updates

    See more
    • Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture

      4/1/24 8:00:00 AM ET
      $LCTX
      $SYBX
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

      – Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and SYNB1353 for homocystinuria (HCU) – - Platform presentation and two poster presentations at SIMD Annual Meeting – – $77.6 million in cash, cash equivalents and marketable securities support projected runway into second half of 2024 –    CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the fourth quarter and full year ending December 31, 2022 and provided a business update. "

      3/29/23 6:40:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development

      CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of Dr. Dave Hava to Head of Research and Development effective January 1, 2023. "Developing a new therapeutic modality requires seamless integration of research and clinical development so that learnings from the clinic can be immediately applied to earlier programs," said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. "Since joining the company, Dave has demonstrated the attributes required

      1/3/23 6:58:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Synlogic upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Synlogic from Perform to Outperform and set a new price target of $7.00

      11/24/21 7:28:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic upgraded by Oppenheimer

      Oppenheimer upgraded Synlogic from Perform to Outperform

      11/24/21 4:55:59 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Synlogic with a new price target

      SVB Leerink reiterated coverage of Synlogic with a rating of Outperform and set a new price target of $11.00 from $15.00 previously

      11/11/21 5:14:48 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYBX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Synlogic Inc.

      10-Q - SYNLOGIC, INC. (0001527599) (Filer)

      5/8/25 4:30:30 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Synlogic Inc.

      10-K/A - SYNLOGIC, INC. (0001527599) (Filer)

      4/30/25 11:57:58 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Synlogic Inc.

      10-K - SYNLOGIC, INC. (0001527599) (Filer)

      3/6/25 4:47:33 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYBX
    Financials

    Live finance-specific insights

    See more

    $SYBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Synlogic Adopts Limited Duration Stockholders Rights Plan

      CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today announced that its Board of Directors (the "Board") has approved the adoption of a limited duration shareholder rights plan (the "Rights Plan") and authorized a dividend distribution of one right ("Right") for each outstanding share of common stock. The dividend distribution will be made on March 1, 2024, payable to stockholders of record on that date, and is not taxable to stockholders. The Rights Plan is effective immediately and has a one-year duration, expiring on February 20, 2025. The Company also

      2/20/24 12:15:26 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study

      Results include -38% reduction in urinary oxalate compared to placebo in Roux-en-Y gastric bypass patients Favorable safety and tolerability, with frequency and severity of adverse events similar across placebo and active arms Synlogic to host webcast today at 8:30 am. ET with Dr. Kyle Wood, Associate Professor, Urology,​ University of Alabama ​at Birmingham  CAMBRIDGE, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that SYNB8802 has demonstrated proof of concept through clinically significant

      12/15/22 6:59:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3

      Positive results include clinically meaningful Phe reductions, with a 60% response rate and 42% reduction in plasma Phe among responders across the study population Consistent, positive measures of activity across all assessed endpoints Company confirms SYNB1934 as candidate for Phase 3 initiation expected in H1 2023 Synlogic to Host Webcast Today at 8:30 a.m. ET CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced positive top-line data from the Phase 2 Synpheny-1 study in phenylketonuri

      10/18/22 6:59:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Shea Richard P was granted 15,000 shares, increasing direct ownership by 2,964% to 15,506 units (SEC Form 4)

      4 - SYNLOGIC, INC. (0001527599) (Issuer)

      4/29/25 4:46:11 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Flynn James P was granted 15,000 shares (SEC Form 4)

      4 - SYNLOGIC, INC. (0001527599) (Issuer)

      4/29/25 4:43:44 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Dooley Mary Beth sold $173 worth of shares (144 units at $1.20), decreasing direct ownership by 1% to 12,901 units (SEC Form 4)

      4 - SYNLOGIC, INC. (0001527599) (Issuer)

      4/3/25 4:30:42 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care